logo
  Join        Login             Stock Quote

Pluristem Therapeutics (PSTI) Reports Status Of Orphan Drug Application For Aplastic Anemia

 November 21, 2012 07:42 AM
 


(By Balaseshan) Pluristem Therapeutics Inc. (NASDAQ: PSTI) reported the status of orphan drug application for aplastic anemia, which was acknowledged by the U.S. Food and Drug Administration (FDA) as a rare disease.

FDA has updated the company on its application to designate Pluristem's PLacental eXpanded (PLX) cells orphan drug status in the treatment of aplastic anemia.

The FDA acknowledged that aplastic anemia is a rare disease with prevalence in the United States of less than 200,000. This serves as confirmation that aplastic anemia is an indication for which candidate treatments are eligible for orphan drug status.

[Related -Top Insider Purchases: APA, AIG, CVRR, LPSN, OPK, PSTI]

The FDA has also requested that Pluristem provide additional information and data for further analysis before the FDA can determine if the PLX cells can qualify for orphan drug designation for aplastic anemia.

Orphan drug designation qualifies a company for several benefits under the Orphan Drug Act of 1983 (ODA), as amended. These benefits include a 7-year period of orphan drug exclusivity upon product approval, a tax credit for certain clinical testing expenses for the orphan drug, written guidance on the non-clinical and clinical studies needed to obtain marketing approval of an orphan drug, and orphan drug grants.

"We look forward to providing the additional information that the FDA needs in connection with our orphan drug status application for Aplastic Anemia. We appreciate the very productive working relationship we have with the FDA, as we present PLX cells as candidates for the treatment of a range of therapeutic indications," stated Zami Aberman, Chairman and CEO of Pluristem.

[Related -Stocks Close Mixed Ahead Of ECB Meet; Facebook (FB) Jumps]

PSTI closed Tuesday's regular session down 0.63% at $3.17. The stock has been trading between $2.02 and $5.00 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageWinter is Coming! Here's My Favorite Seasonal Trade

Over the years, I've been successful trading weather patterns as they relate to commodities such as crude read on...

article imageHow To Avoid 5 Common Investing Mistakes

When it comes to successful investing, the field of behavioral finance has shown that sometimes the worst read on...

article imageSector Detector: Bulls Go Down Swinging, Refusing To Give Up Much Ground

Although the stock market displayed weakness last week as I suggested it would, bulls aren’t going down read on...

article imageThe Bumpy Road Ahead To Policy Normalization

When the dust clears from tomorrow’s Fed announcement, the crowd’s expecting that the slow but persistent read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.